News Medical

Harnessing complement proteins: Transforming the landscape of immunotherapy

The complement system has more than 50 soluble and membrane-bound proteins. In innate and adaptive immunity, complement is essential for eliminating foreign pathogens and apoptotic cells. It is also ...
Nature

Structure of and influence of a tick complement inhibitor on human complement component 5

To provide insight into the structural and functional properties of human complement component 5 (C5), we determined its crystal structure at a resolution of 3.1 Å. The core of C5 adopted a structure ...
Business Wire

Ra Pharmaceuticals Announces Initiation of First-in-Human Clinical Trial of Novel Complement C5 Inhibitor

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals announced today that it has launched a Phase 1 study of its synthetic peptide C5 inhibitor, RA101495. The Phase 1 trial is a randomized, ...
PharmiWeb

Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

-- Phase 1 Multiple Ascending Dose Study of RLYB116 Ongoing; Preliminary Safety, PK, and PD Data Expected in 4Q 2023 -- NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a ...
FierceBiotech

Alnylam Reports Positive Initial Clinical Results for ALN-CC5, an Investigational RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated ...

CAMBRIDGE, Mass.--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced initial positive results from its ongoing Phase 1/2 clinical trial with ALN-CC5, an ...